Brief: Trevi Therapeutics Announces Results From Phase 2B/3 Prism Open-Label Extension Study Of Haduvio™ In Prurigo Nodularis

Trevi Therapeutics

13/10/2023 13:33

Oct 13 (Reuters) - Trevi Therapeutics Inc  TRVI.O :
    * TREVI THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 2B/3 PRISM
OPEN-LABEL EXTENSION STUDY OF HADUVIO™ IN PRURIGO NODULARIS
    * TREVI THERAPEUTICS INC - SAFETY DATA OVER 52 WEEKS:
TREATMENT
WAS WELL TOLERATED AND CONSISTENT WITH 14-WEEK BLINDED SAFETY
DATA
    * TREVI THERAPEUTICS INC - CONTINUED REDUCTION IN WI-NRS
OBSERVED
AMONG PARTICIPANTS WHO REMAINED IN STUDY THROUGH 52 WEEKS OF
TREATMENT

Source text for Eikon:  ID:nPn4RYGQca 
Further company coverage:  TRVI.O 

 ((Reuters.Briefs@thomsonreuters.com))